Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The HLA-DR3 haplotype is associated with increased risk of myasthenia gravis (MG) and a number of other autoimmune diseases, including insulin-dependent diabetes mellitus (IDDM), coeliac disease, and premature ovarian failure (POF). With a cDNA probe for a DQ beta gene, a 15 kb Hinc II restriction fragment has been demonstrated in genomic DNA from 7 of 16 HLA-DR3 patients with MG, 1 of 19 healthy DR3 controls, and none of 24 DR3 patients with IDDM, coeliac disease, or POF. The HLA-DQ polymorphism may be closely linked to a genetic locus regulating immune responsiveness to acetylcholine receptor and susceptibility to MG.

Original publication




Journal article


Lancet (London, England)

Publication Date





1058 - 1060


Humans, Celiac Disease, Myasthenia Gravis, Ovarian Diseases, Diabetes Mellitus, Type 1, DNA Restriction Enzymes, Genetic Markers, Histocompatibility Antigens Class II, HLA-DQ Antigens, HLA-DR3 Antigen, Hybridization, Genetic, Polymorphism, Genetic, Female, Genetic Carrier Screening